Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,211.00+0.36%ETH$2,430.35+0.73%GOLD$4,368.20-0.44%OIL$100.70-1.69%
Smart Investors Daily
EN

NASDAQ · ENTX

Entera Bio Ltd.

Healthcare · Biotechnology

$2.96

Up+$0.10 (+3.50%)

Updated Sep 17, 2026, 11:01 AM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
101.79M
P/E ratio
-41.77
Dividend yield
0.00%
52-week range
$0.91 – $4.20
Volume
777.61K
Avg. volume
154.41K

Price performance

ENTX price history

1M range · 0 trading sessions · Daily adjusted prices

ENTX does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ENTX news

The latest Smart Investors Daily articles mentioning ENTX.

Stock researchCompany · Overview

ENTX research

Overview

Company profile and research snapshot.

Company profile

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ENTX recent ratings
DateFirmRatingTarget
Apr 27, 2026HC Wainwright & Co.Buy—
Feb 9, 2026HC Wainwright & Co.Buy—
Mar 18, 2025HC Wainwright & Co.Buy—
Nov 11, 2024HC Wainwright & Co.Buy—
Oct 7, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 27, 2026

Correction: Entera to Participate in Upcoming Fall Investor Conferences

TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences: 2026 Cantor Global Healthcare ConferenceFireside Chat: September 10, 2026 at 1:00 p.m. Eastern Time, Waldorf Astoria New York, 301 Park Avenue, New York, NY Guggenheim Securities 3rd Annual

Yahoo · Aug 27, 2026

Entera to Participate in Upcoming Fall Investor Conferences

TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences: 2026 Cantor Global Healthcare ConferenceFireside Chat: September 10, 2026 at 1:00 p.m. Eastern Time, Waldorf Astoria New York, 301 Park Avenue, New York, NY 2026 Leerink Partners Biopharma

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By